Vertex Pharmaceuticals Inc (VRTX.OQ)
78.78USD
11:38am EDT
$-1.94 (-2.40%)
$80.72
$80.68
$81.08
$78.52
148,210
578,582
$89.96
$38.44
About
Overall
| Beta: | 0.39 |
| Market Cap (Mil.): | $18,741.33 |
| Shares Outstanding (Mil.): | 232.18 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| VRTX.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 44.65 | 37.87 |
| EPS (TTM): | -2.31 | -- | -- |
| ROI: | -24.14 | -2.30 | 18.70 |
| ROE: | -42.25 | -2.12 | 19.53 |
Vertex loss narrows as cystic fibrosis drug sales grow
- Vertex Pharmaceuticals Inc on Monday posted a narrower quarterly loss on stronger-than-expected demand for its cystic fibrosis treatment, and it raised its full-year forecast for sales of the medicine.
UPDATE 3-Vertex loss narrows as cystic fibrosis drug sales grow
July 29 - Vertex Pharmaceuticals Inc on Monday posted a narrower quarterly loss on stronger-than-expected demand for its cystic fibrosis treatment, and it raised its full-year forecast for sales of the medicine.
Vertex loss narrows as demand for cystic fibrosis drug strong
July 29 - Vertex Pharmaceuticals Inc, which last week had an experimental oral hepatitis drug placed on partial clinical hold by U.S. health regulators, posted a narrower quarterly loss on stronger-than-expected demand for its cystic fibrosis treatment.
CORRECTED-UPDATE 1-U.S. FDA puts hold on Vertex hepatitis study
(Corrects third paragraph to show hold on U.S. trial, not European study)
CORRECTED-FDA puts hold on Vertex oral hepatitis drug trial and shares fall
(Corrects third paragraph to show hold on U.S. trial, not European study)
Gilead profit rises, shares jump on Vertex hepatitis setback
- Shares of biotechnology company Gilead Sciences Inc jumped more than 5 percent late Thursday after rival Vertex Pharmaceuticals Inc announced a setback in development of its experimental hepatitis C drug.
UPDATE 2-Gilead profit rises, shares jump on Vertex hepatitis setback
* Gilead is biggest maker of branded drugs to treat HIV (Adds company and analyst comments, updates share price)
Vertex posts loss, raises cystic fibrosis sales view
- Vertex Pharmaceuticals Inc on Tuesday increased by $20 million the 2013 forecast for sales of its cystic fibrosis drug Kalydeco, and said it anticipates seeking approval in 2014 of a CF combination therapy that has become a focus for investors.
UPDATE 3-Vertex posts loss, raises cystic fibrosis sales view
April 30 - Vertex Pharmaceuticals Inc on Tuesday increased by $20 million the 2013 forecast for sales of its cystic fibrosis drug Kalydeco, and said it anticipates seeking approval in 2014 of a CF combination therapy that has become a focus for investors.
Vertex posts quarterly loss as hepatitis C drug sales fall
April 30 - Vertex Pharmaceuticals Inc on Tuesday reported a fourth successive quarterly loss as sales of its hepatitis C drug, Incivek, continued to plunge, but the biotechnology company raised its forecast for sales of a cystic fibrosis drug that has become the focus for investors.
Competitors
| Price | Change | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $94.02 | +0.25 |
| Pfizer Inc. (PFE.N) | $29.27 | +0.16 |
| Novartis AG (NOVN.VX) | CHF67.55 | +0.95 |
| Merck & Co., Inc. (MRK.N) | $48.39 | -0.19 |
| Roche Holding Ltd. (ROG.VX) | CHF228.70 | +0.70 |
| Sanofi SA (SASY.PA) | €76.36 | -0.49 |
| GlaxoSmithKline plc (GSK.L) | 1,712.50p | 0.00 |
| AbbVie Inc (ABBV.N) | $45.25 | +0.00 |
| Bristol Myers Squibb Co. (BMY.N) | $43.98 | -0.01 |
| Bristol Myers Squibb Co. (BMYMP.PK) | -- | -- |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: Pechala's Reports
|
$25.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

